Resistance of Cynomolgus Monkeys to Nipah and Hendra Virus Disease Is Associated With Cell-Mediated and Humoral Immunity.
Nipah virus
Hendra virus
animal model
chemokines
cytokines
henipavirus
paramyxovirus
pathogenesis
primate
transcriptomics
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
11 05 2020
11 05 2020
Historique:
pubmed:
6
2
2020
medline:
23
2
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
The henipaviruses, Hendra virus (HeV) and Nipah virus (NiV), are capable of causing severe and often lethal respiratory and/or neurologic disease in animals and humans. Given the sporadic nature of henipavirus outbreaks, licensure of vaccines and therapeutics for human use will likely require demonstration of efficacy in animal models that faithfully reproduce the human condition. Currently, the African green monkey (AGM) best mimics human henipavirus-induced disease. The pathogenic potential of HeV and both strains of NiV (Malaysia, Bangladesh) was assessed in cynomolgus monkeys and compared with henipavirus-infected historical control AGMs. Multiplex gene and protein expression assays were used to compare host responses. In contrast to AGMs, in which henipaviruses cause severe and usually lethal disease, HeV and NiVs caused only mild or asymptomatic infections in macaques. All henipaviruses replicated in macaques with similar kinetics as in AGMs. Infection in macaques was associated with activation and predicted recruitment of cytotoxic CD8+ T cells, Th1 cells, IgM+ B cells, and plasma cells. Conversely, fatal outcome in AGMs was associated with aberrant innate immune signaling, complement dysregulation, Th2 skewing, and increased secretion of MCP-1. The restriction factors identified in macaques can be harnessed for development of effective countermeasures against henipavirus disease.
Sections du résumé
BACKGROUND
The henipaviruses, Hendra virus (HeV) and Nipah virus (NiV), are capable of causing severe and often lethal respiratory and/or neurologic disease in animals and humans. Given the sporadic nature of henipavirus outbreaks, licensure of vaccines and therapeutics for human use will likely require demonstration of efficacy in animal models that faithfully reproduce the human condition. Currently, the African green monkey (AGM) best mimics human henipavirus-induced disease.
METHODS
The pathogenic potential of HeV and both strains of NiV (Malaysia, Bangladesh) was assessed in cynomolgus monkeys and compared with henipavirus-infected historical control AGMs. Multiplex gene and protein expression assays were used to compare host responses.
RESULTS
In contrast to AGMs, in which henipaviruses cause severe and usually lethal disease, HeV and NiVs caused only mild or asymptomatic infections in macaques. All henipaviruses replicated in macaques with similar kinetics as in AGMs. Infection in macaques was associated with activation and predicted recruitment of cytotoxic CD8+ T cells, Th1 cells, IgM+ B cells, and plasma cells. Conversely, fatal outcome in AGMs was associated with aberrant innate immune signaling, complement dysregulation, Th2 skewing, and increased secretion of MCP-1.
CONCLUSION
The restriction factors identified in macaques can be harnessed for development of effective countermeasures against henipavirus disease.
Identifiants
pubmed: 32022850
pii: 5727782
doi: 10.1093/infdis/jiz613
pmc: PMC7213570
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S436-S447Subventions
Organisme : NIAID NIH HHS
ID : U01 AI082121
Pays : United States
Organisme : NIAID NIH HHS
ID : UC7 AI094660
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Patholog Res Int. 2011;2011:567248
pubmed: 21961078
J Clin Invest. 2004 Dec;114(12):1812-9
pubmed: 15599406
J Immunol. 2002 Nov 1;169(9):4861-6
pubmed: 12391196
PLoS Negl Trop Dis. 2017 Apr 7;11(4):e0005532
pubmed: 28388650
Emerg Infect Dis. 2007 Jul;13(7):1031-7
pubmed: 18214175
Eur J Immunol. 2009 Jun;39(6):1632-41
pubmed: 19499526
J Immunol. 1998 Dec 15;161(12):6871-7
pubmed: 9862719
J Clin Microbiol. 2018 May 25;56(6):
pubmed: 29643201
N Engl J Med. 2019 May 9;380(19):1804-1814
pubmed: 31067370
J Infect Dis. 2020 May 11;221(Supplement_4):S414-S418
pubmed: 31665362
Blood. 1995 Oct 1;86(7):2534-40
pubmed: 7670098
Cell. 1996 Oct 18;87(2):307-17
pubmed: 8861914
J Virol. 2014 May;88(9):4624-31
pubmed: 24522928
J Clin Invest. 2009 Dec;119(12):3544-55
pubmed: 19959873
J Infect Dis. 2019 May 24;219(12):1867-1878
pubmed: 30364984
Sci Rep. 2017 Nov 7;7(1):14756
pubmed: 29116224
Ther Innov Regul Sci. 2016 Sep;50(5):660-670
pubmed: 30231765
Nature. 2018 Jan 3;553(7686):77-81
pubmed: 29300007
Emerg Infect Dis. 2012 Feb;18(2):248-55
pubmed: 22304936
Emerg Infect Dis. 2019 Jun;25(6):1144-1152
pubmed: 31107231
Zoonoses Public Health. 2013 Feb;60(1):69-83
pubmed: 22709528
PLoS One. 2011;6(12):e28678
pubmed: 22174865
Front Microbiol. 2018 Nov 13;9:2747
pubmed: 30483242
Microbes Infect. 2012 Mar;14(3):247-61
pubmed: 22064066
Clin Dev Immunol. 2012;2012:925135
pubmed: 22474485
Rev Med Virol. 2019 Jan;29(1):e2010
pubmed: 30251294
J Virol. 2008 Apr;82(7):3713-24
pubmed: 18216122
Sci Rep. 2016 Aug 03;6:30916
pubmed: 27484128
Sci Transl Med. 2014 Jun 25;6(242):242ra82
pubmed: 24964990
Clin Infect Dis. 2009 Dec 1;49(11):1743-8
pubmed: 19886791
J Biol Chem. 2000 May 26;275(21):16174-82
pubmed: 10748115
PLoS Negl Trop Dis. 2018 Nov 21;12(11):e0006978
pubmed: 30462637
Emerg Infect Dis. 2005 Oct;11(10):1594-7
pubmed: 16318702
Proc Natl Acad Sci U S A. 1988 Jan;85(1):208-12
pubmed: 2448768
Science. 2000 May 26;288(5470):1432-5
pubmed: 10827955
Curr Top Microbiol Immunol. 2012;359:153-77
pubmed: 22476556
Virus Res. 2015 Apr 16;202:112-9
pubmed: 25455336
Blood. 1992 Mar 15;79(6):1538-44
pubmed: 1339298
J Virol. 2011 Aug;85(15):7863-71
pubmed: 21593145
J Virol. 2010 Oct;84(19):9831-9
pubmed: 20660198
J Infect Dis. 2020 May 11;221(Supplement_4):S431-S435
pubmed: 31665351
Cell. 2000 Mar 17;100(6):655-69
pubmed: 10761931
J Am Assoc Lab Anim Sci. 2014 May;53(3):278-82
pubmed: 24827570
J Exp Med. 1992 Dec 1;176(6):1521-9
pubmed: 1460416
Int J Biochem Cell Biol. 2002 May;34(5):427-31
pubmed: 11906815
PLoS Negl Trop Dis. 2019 Jun 5;13(6):e0007454
pubmed: 31166946
Emerg Infect Dis. 2015 Feb;21(2):328-31
pubmed: 25626011
PLoS One. 2010 May 18;5(5):e10690
pubmed: 20502528